Company Product Description Indication Status
Acadia Pharmaceuticals Inc., of San Diego Nuplazid (pimavanserin) Selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors Hallucinations and delusions associated with dementia-related psychosis Submitted supplementary NDA to the FDA
Aldeyra Therapeutics Inc., of Lexington, Mass. ADX-2191 Inhibits dihydrofolate reductase Proliferative vitreoretinopathy European Commission granted orphan medicinal product designation
Genocea Biosciences Inc., of Cambridge, Mass. GEN-011 T-cell therapy Tumors Submitted IND to FDA for a phase I/IIa study; preliminary data expected in mid-2021
Merck & Co. Inc., of Kenilworth, N.J. Gardasil9 HPV vaccine Prevention of oropharyngeal and other head and neck cancers FDA approved the expanded indication
Neoimmunetech Inc., of Rockville, Md. NT-I7 (efineptakin alfa) Long-acting human IL-7 Progressive multifocal leukoencephalopathy FDA granted orphan drug designation
Sunovion Pharmaceuticals Inc., of Mississauga, Ontario Kynmobi (apomorphine hydrochloride) Dopamine agonist Off episodes in patients with Parkinson’s disease Health Canada approved the drug
Viiv Healthcare, of London Tivicay PD (dolutegravir)  Integrase strand transfer inhibitor HIV infection FDA approved the tablets for oral suspension

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments